Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on August 29, 2019, reporting events occurring on August 24, 2019. The filing details an amendment to a Collaboration and License Agreement with BioSense Global LLC regarding the development and commercialization of the pharmaceutical product RX-3117.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial figure disclosed is a $1.5 million upfront payment (License Fee) owed by BioSense to the Company.
Material Changes
- Payment Extension: The due date for the final installment of the $1.5 million License Fee was extended from August 24, 2019, to September 23, 2019.
- Agreement Status: The exclusive license for RX-3117 in Singapore, China, Hong Kong, Macau, and Taiwan remains contingent upon the full payment of the License Fee.
Outlook, Risks, and Contingencies
Management highlights significant risks associated with the forward-looking nature of the payment and product development. Key uncertainties include:
- BioSense's potential decision not to make the required payment.
- BioSense seeking further delays or modifications to the Agreement.
- Actual results may differ materially from expectations due to these uncertainties.
The Company explicitly states it undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the actual receipt of the $1.5 million payment by the September 23, 2019 deadline.
- Confirm whether the exclusive license for RX-3117 in the specified Asian territories has been activated.
- Review subsequent filings for any further amendments or defaults regarding the BioSense agreement.
- Check the Company's most recent Form 10-K and 10-Q for broader liquidity and cash position context not provided in this 8-K.